COST-EFFECTIVENESS OF PEMBROLIZUMAB IN PATIENTS WITH ADVANCED MELANOMA PREVIOUSLY TREATED WITH IPILIMUMAB IN PORTUGAL

被引：0
|
作者：
Silva Miguel, L. [1 ]
Vargas Lopes, F. [2 ]
Pinheiro, B. [1 ]
Wang, J. [3 ]
Xu, R. [3 ]
Pellissier, J. [3 ]
Laires, P. A. [2 ]
机构：
[1] Res Ctr Portuguese Econ ISEG ULisboa, Lisbon, Portugal
[2] Merck Sharp & Dohme Ltd, Oeiras, Portugal
[3] Merck & Co Inc, N Wales, PA USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN121
引用
收藏
页码：A730 / A730
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF IPILIMUMAB IN PREVIOUSLY TREATED PATIENTS FOR ADVANCED MELANOMA IN PORTUGAL
    Radford, M.
    Cortes, P.
    Carrasco, J.
    Gueron, B.
    Goncalves, F.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A139 - A139
  • [2] COST-EFFECTIVENESS OF IPILIMUMAB IN PREVIOUSLY UNTREATED PATIENTS FOR ADVANCED MELANOMA IN SWEDEN
    Barzey, V
    Asukai, Y.
    Gueron, B.
    Holmberg, C.
    Kotapati, S.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A642 - A643
  • [3] COST-EFFECTIVENESS OF PEMBROLIZUMAB FOR ADVANCED MELANOMA TREATMENT IN PORTUGAL
    Silva Miguel, L.
    Vargas Lopes, F.
    Pinheiro, B.
    Wang, J.
    Xu, R.
    Pellissier, J.
    Laires, P. A.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A729 - A729
  • [4] COST-EFFECTIVENESS OF PEMBROLIZUMAB (KEYTRUDA®) VERSUS IPILIMUMAB IN PATIENTS WITH ADVANCED MELANOMA IN CANADA
    Wang, J.
    Chabot, I
    El-Hadi, W.
    Xu, R.
    Pellissier, J.
    Iliopoulos, I.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A153 - A154
  • [5] COST-EFFECTIVENESS OF IPILIMUMAB FOR PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED METASTATIC MELANOMA IN SPAIN
    Aceituno, S.
    Canal, C.
    Paz, S.
    Gonzalez, P.
    Marquez-Rodas, I
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A631 - A631
  • [6] COST EFFECTIVENESS OF PEMBROLIZUMAB AND IPILIMUMAB IN ADVANCED MELANOMA
    Lu, T.
    Hay, J. W.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A149 - A149
  • [7] Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naive Patients with Advanced Melanoma in the United States
    Wang, Jingshu
    Chmielowski, Bartosz
    Pellissier, James
    Xu, Ruifeng
    Stevinson, Kendall
    Liu, Frank Xiaoqing
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2017, 23 (02): : 158 - 158
  • [8] MODELLING THE COST-EFFECTIVENESS OF IPILIMUMAB FOR PREVIOUSLY-TREATED, METASTATIC MELANOMA
    Lee, D.
    Winn, B.
    Lebmeier, M.
    Batty, A.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A423 - A423
  • [9] Cost Effectiveness of Pembrolizumab for Advanced Melanoma Treatment in Portugal
    Miguel, Luis Silva
    Lopes, Francisca Vargas
    Pinheiro, Bernardete
    Wang, Jingshu
    Xu, Ruifeng
    Pellissier, James
    Laires, Pedro Almeida
    [J]. VALUE IN HEALTH, 2017, 20 (08) : 1065 - 1073
  • [10] Ipilimumab In Previously Treated Patients with Advanced Melanoma
    Sanford, Mark
    [J]. BIODRUGS, 2012, 26 (03) : 185 - 193
12345